Literature DB >> 17533510

Recurrent infrasellar clival craniopharyngioma.

B T Ragel1, F S Bishop, W T Couldwell.   

Abstract

The patient is a 44-year-old man who underwent resection of a posterior nasopharynx tumor 12 years earlier via left lateral rhinotomy approach. The final pathological analysis indicated the tumor was a craniopharyngioma, and the patient subsequently underwent focal radiation. The patient returned to medical attention complaining of dysequilibrium. A neurologic exam was nonfocal. Magnetic resonance imaging revealed a clival mass, separate from the sella turcica, with imaging characteristics concerning for chordoma or primary bone tumor (Fig. 1). The lesion was resected via an endoscope-assisted endonasal transsphenoidal approach, with gross total resection achieved. Intraoperatively, the mass was noted to erode through the posterior nasopharynx, without extension superiorly into the sella or posteriorly through the clival dura (i.e., lesion was infrasellar). The final pathological results indicated the tumor was adamantinomatous craniopharyngioma.

Entities:  

Mesh:

Year:  2007        PMID: 17533510     DOI: 10.1007/s00701-007-1168-3

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  3 in total

1.  Endocrinologic, neurologic, and visual morbidity after treatment for craniopharyngioma.

Authors:  Michael E Sughrue; Isaac Yang; Ari J Kane; Shanna Fang; Aaron J Clark; Derrick Aranda; Igor J Barani; Andrew T Parsa
Journal:  J Neurooncol       Date:  2010-06-10       Impact factor: 4.130

2.  Remote delayed recurrence of craniopharyngioma after radiotherapy.

Authors:  Chidambaram Balasubramaniam; Santosh Rao Mohan; K Subramaniam
Journal:  J Pediatr Neurosci       Date:  2015 Jan-Mar

3.  An infrasellar craniopharyngioma involving the sphenoid sinus and clivus.

Authors:  Zhong Zhang; Ming-Yang Li; Yan-Wei Liu; Yong-Zhi Wang
Journal:  Chin Med J (Engl)       Date:  2015-03-20       Impact factor: 2.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.